Other research has indicated that EGFR mutations predict poor prognosis for NSCLC patients treated with VRB in combination with platinum-based chemotherapy, with evidence of variable treatment-response according to occurring co-mutations [19]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.